Particle.news
Download on the App Store

Study Identifies NPM1 as a Potential Target in WNT‑Driven Bowel and Some Liver Cancers

A Nature Genetics paper from the Cancer Research UK Scotland Institute reports preclinical evidence that NPM1 removal stalls tumour growth, suggesting a therapeutic window because normal adult tissues do not depend on it.

Overview

  • - Researchers found high levels of nucleophosmin (NPM1) in bowel cancer and some liver cancers linked to faults in the WNT signalling pathway.
  • - Laboratory work showed that eliminating NPM1 disrupts cancer cell protein production and triggers a tumour suppressor that halts growth.
  • - The team plans to pursue drugs that block NPM1, with development at an early, preclinical stage and no therapies yet in trials.
  • - The work forms part of the Cancer Grand Challenges SpecifiCancer initiative co‑funded by Cancer Research UK and the Mark Foundation.
  • - The findings come as early‑onset bowel cancer rises in many countries, with faster increases reported in young women in Scotland and England.